Tracing proliferating potential of lung tumours by [11C]Nicotinamide

Authors

  • Robert Bielik Cancer Research UK Scotland Institute
  • Gavin Brown Cancer Research UK Scotland Institute
  • Dmitry Solovyev School of Cancer Sciences, University of Glasgow
  • David Lewis Cancer Research UK Scotland Institute

DOI:

https://doi.org/10.2218/piwjournal.9852

Abstract

Many tumours rely on aerobic glycolysis, known as the Warburg effect, to satisfy energy needs and sustain rapid proliferation [1]. High demands of glucose in tumours can be measured by [18F[fluorodeoxyglucose, [18F]FDG, positron emission tomography (PET). Nicotinamide adenine dinucleotide (NAD) is a coenzyme involved in redox reactions in many metabolic pathways, including glycolysis. To maintain the high rates of glycolysis and proliferation, tumours need increased NAD+ levels and use nicotinamide for the upregulated NAD+ salvage pathway that is the main source of NAD+ in proliferative cancer cells [2].  Herein, we show an improved synthesis method of [11C]Nicotinamide, [11C]NAM, and studied the uptake of [11C]NAM and [18F]FDG to measure proliferating capacity in a lung cancer model.

[Carboxyl-11C]nicotinamide was synthesized by a one-pot radiolabeling method [3] on the SYNTHRA synthesizer (Synthra GmbH, Germany) (see Figure 1A). We used a KrasG12D/+ genetically engineered mouse model of lung cancer and evaluated the uptake of [11C]nicotinamide and [18F]FDG with dual-tracer sequential imaging protocol (see Figure 1B) using a NanoScan PET/MRI scanner (Mediso Medical Imaging Systems, Hungary).

We obtained [carboxyl-11C]nicotinamide in a radiochemical yield of 15 ± 5 %, volumic activity of 50 ± 10 MBq/ml, and radiochemical purity was > 99 %.  We optimized the imaging protocol and found the uptake of [11C]nicotinamide co-localized with the uptake of [18F]FDG in the KrasG12D/+ model of lung cancer as shown in Figure 1C suggesting the higher NAM uptake was associated with high NAD+ production in highly proliferating tumours.

We demonstrated that metabolic PET/MRI imaging with [11C]NAM can complement [18F]FDG PET and be useful for probing proliferative potential in lung cancer. This method could be translated and applied in clinical practice to enable visualization of NAD+ metabolism in lung tumours and targeted therapeutically.

Please click on the 'PDF' for the full abstract!

Downloads

Published

08-Oct-2024